Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Burkitt Lymphoma 19Lymphoma, Large B-Cell, Diffuse 15Multiple Myeloma 14Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 11Lymphoma 11Leukemia, Myeloid, Acute 11Recurrence 10Ovarian Neoplasms 8Myelodysplastic Syndromes 8Lymphoma, B-Cell 8Pancreatic Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia 7Lymphoma, Mantle-Cell 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Hodgkin Disease 6Hematologic Neoplasms 6Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myelomonocytic, Chronic 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Sarcoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Osteosarcoma 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, B-Cell, Marginal Zone 4

Interventions

ruxolitinib 1idecabtagene vicleucel 1fludarabine 1Leukapheresis 1Lenalidomide 1Cyclophosphamide 1CPI-0610 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Cyclophosphamide × 30 days × Clear all
NCT05032820 2026-05-19

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Medical College of Wisconsin

Phase 2 Completed
40 enrolled 32 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡